Keegan, Michael R. http://orcid.org/0000-0002-6924-7242
Winston, Alan
Higgs, Chris
Fuchs, Dietmar
Boasso, Adriano
Nelson, Mark
Funding for this research was provided by:
ViiV Healthcare
Article History
Received: 15 August 2018
Revised: 4 October 2018
Accepted: 19 October 2018
First Online: 26 November 2018
Compliance with ethical standards
: The study team complied with the ethical principles for medical research involving human subjects as defined by the World Medical Associations’ Declaration of Helsinki. This study was reviewed and approved by the London Research Ethics Committee (REC reference 14/LO/1493, Date 31/10/2014; EudraCT number 2013-004729-94).
: ViiV Healthcare Ltd. provided full financial support and supply of dolutegravir for the study. The authors confirm that the funders had no influence over the study design, content of the article, or selection of this journal.Michael Keegan participated in this work as part of a PhD, which is being conducted at Imperial College London and is sponsored with an unrestricted grant by ViiV Healthcare Ltd. He is an employee and shareholder in ViiV Healthcare Ltd.Mark Nelson has received payments from ViiV Healthcare Ltd. for advisory board participation and travel.Alan Winston has received speaker fees and investigator-initiated grants from ViiV Healthcare Ltd.Dietmar Fuchs, Chris Higgs and Adriano Boasso declare that they have no conflict of interest.